Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The stock's fall snapped a four-day winning streak.

The stock exceeded the S&P 500 ... The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its ...

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories ( ABT -1.00%), AbbVie ( ABBV 2.86%), ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

In this note, we discuss Pfizer’s stock performance, key takeaways from its recent results, and valuation. PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...